RENISHAW PLC

Their core work

Renishaw is a large UK-based precision engineering and metrology company that designs and manufactures high-accuracy measurement systems, additive manufacturing equipment, and medical devices — particularly stereotactic neurosurgical robots. In H2020, they contributed precision hardware and drug delivery device expertise to projects spanning neurosurgery, Parkinson's disease treatment, advanced manufacturing processes, and graphene-based technologies. Their involvement consistently centres on bringing industrial precision engineering into medical and manufacturing applications.

What they specialise in

How they've shifted over time

Renishaw's early H2020 involvement (2015-2016) focused on precision engineering applications in neurosurgery and advanced materials — projects like EDEN2020 addressed minimally invasive brain surgery through robotic delivery systems. By 2017, their focus shifted deeper into clinical translation, with TreatER targeting Parkinson's disease treatment via intracerebral administration of CDNF protein, and SUPREME addressing sustainable manufacturing processes. The trajectory shows a company moving from device engineering toward clinical-stage medical applications while maintaining its manufacturing roots.

Renishaw is deepening its medical device portfolio toward clinical-stage brain drug delivery, making them a strong partner for translational neuroscience and neurodegenerative disease projects.

How they like to work

Renishaw participates exclusively as a consortium partner, never leading projects — consistent with a large industrial company contributing specialised hardware and engineering expertise to research-driven consortia. With 60 unique partners across 14 countries from just 5 projects, they operate in large, diverse consortia and do not appear to cluster around repeat partners. This suggests they are accessible and experienced consortium members who integrate well into multi-disciplinary teams.

Renishaw has built a broad European network of 60 unique partners spanning 14 countries through just 5 projects, indicating participation in large consortia with strong geographic diversity. No single country dominance is apparent beyond the UK base.

What sets them apart

Renishaw bridges precision engineering and clinical neuroscience in a way very few industrial companies can — they don't just build measurement tools, they build implantable drug delivery devices tested in Parkinson's clinical trials. This combination of manufacturing-grade engineering rigour with medical device capability makes them uniquely valuable for translational health projects that need hardware partners who understand both the factory floor and the operating theatre. Their large-company stability and broad IP portfolio also reduce risk for consortia needing a reliable industrial anchor.

Highlights from their portfolio

• EDEN2020
  Largest single EC contribution (EUR 1.16M) — focused on next-generation minimally invasive neurosurgery delivery systems, a flagship application of Renishaw's stereotactic technology.
• TreatER
  A clinical-stage study delivering CDNF protein directly into the brain for Parkinson's disease — rare for an engineering company to participate in a clinical trial, demonstrating deep medical device maturity.
• SUPREME
  Addressed sustainable powder metallurgy processes, directly aligned with Renishaw's commercial additive manufacturing systems and showing their commitment to greener production methods.